Title Outcomes and risk factors of critically ill patients with hematological malignancy. prospective single‐centre observational study /
Authors Judickas, Šarūnas ; Stasiūnaitis, Raimundas ; Žučenka, Andrius ; Žvirblis, Tadas ; Šerpytis, Mindaugas ; Šipylaitė, Jūratė
DOI 10.3390/medicina57121317
Full Text Download
Is Part of Medicina.. Basel : MDPI. 2021, vol. 57, iss. 12, art. no. 1317, p. [1-12].. ISSN 1010-660X. eISSN 1648-9144
Keywords [eng] blood cancer ; oncohematological patients ; intensive care unit ; outcome ; Baltic region
Abstract [eng] Background and Objectives: Oncohematological patients have a high risk of mortality when they need treatment in an intensive care unit (ICU). The aim of our study is to analyze the outcomes of oncohemathological patients admitted to the ICU and their risk factors. Materials and Methods: A prospective single‐center observational study was performed with 114 patients from July 2017 to December 2019. Inclusion criteria were transfer to an ICU, hematological malignancy, age >18 years, a central line or arterial line inserted or planned to be inserted, and a signed informed consent form. Univariate and multivariable logistic regression models were used to evaluate the potential risk factors for ICU mortality. Results: ICU mortality was 44.74%. Invasive mechanical ventilation in ICU was used for 55.26% of the patients, and vasoactive drugs were used for 77.19% of patients. Factors independently associated with it were qSOFA score ≥2, increase of SOFA score over the first 48 h, mechanical ventilation on the first day in ICU, need for colistin therapy, lower arterial pH on arrival to ICU. Cut‐off value of the noradrenaline dose associated with ICU mortality was 0.21 μg/kg/min with a ROC of 0.9686 (95%CI 0.93–1.00, p < 0.0001). Conclusions: Mortality of oncohematological patients in the ICU is high and it is associated with progression of organ dysfunction over the first 48 h in ICU, invasive mechanical ventilation and need for relatively low dose of noradrenaline. Despite our findings, we do not recommend making decisions regarding treatment limitations for patients who have reached cut‐off dose of noradrenaline.
Published Basel : MDPI
Type Journal article
Language English
Publication date 2021
CC license CC license description